Posterior uveal melanoma is a rare eye cancer that starts in the back part of the eye, usually in adults. Early symptoms of posterior uveal melanoma can include blurred vision, flashes, floaters, or a dark spot in vision, but some people have no symptoms at first. A routine checkup can sometimes be the first step toward diagnosis, because posterior uveal melanoma may be found during a dilated eye exam. It can be a serious condition because it may spread to other parts of the body, especially the liver, and the outlook depends on the size of the tumor and whether it has spread. Treatment for posterior uveal melanoma often includes radiation, laser treatment, surgery, or close monitoring in selected cases.
How many people live with Posterior uveal melanoma?
Posterior uveal melanoma is so rare that there is no single, up-to-date source that reliably reports how many people are living with it worldwide or in the United States. Most trusted sources track how many new cases are diagnosed each year instead of a current living total, so a dependable global or U.S. estimate is not available.
Overview
Posterior uveal melanomaSymptoms
Posterior uveal melanoma often causes no early symptoms. When signs do appear, people with posterior uveal melanoma may notice blurred vision, flashes or floaters, a dark spot in vision, or less often eye pain.
Outlook and prognosis
For people with posterior uveal melanoma, outlook depends mainly on tumor size, location, and whether it has spread beyond the eye. Many do well after treatment in the eye, but ongoing follow-up is important because spread can happen years later.
Causes and risk factors
Posterior uveal melanoma usually develops from DNA changes in pigment cells, often by chance. Risk rises with older age, lighter eye color, fair skin, and inherited rare gene changes. Long-term ultraviolet light is not a proven main cause.
Genetic influences
Genetics matter a lot in posterior uveal melanoma. Most cases are not inherited, but gene changes in the tumor help guide prognosis, and rarely an inherited change can raise risk for posterior uveal melanoma in families.
Diagnosis
Posterior uveal melanoma is usually diagnosed during a dilated eye exam. Eye imaging, often including ultrasound and retinal scans, helps confirm the diagnosis of posterior uveal melanoma and measure its size. Some people also need blood tests or scans to check spread.
Treatment and drugs
Posterior uveal melanoma is often treated with focused radiation, usually a small radioactive plaque or proton beam therapy, to control the eye tumor. Some people need laser treatment or surgery, including eye removal. If it spreads, drug treatment may include immunotherapy or targeted therapy.
Symptoms
Changes in one eye can be easy to miss at first, especially if the other eye still sees well. You might notice small changes at first, such as blur, flashes, floaters, or a growing shadow in part of your vision. Posterior uveal melanoma often causes no symptoms early on and is sometimes found during a routine dilated eye exam. The early symptoms of posterior uveal melanoma can overlap with other eye problems, so new vision changes should be checked promptly.
Posterior uveal melanoma may cause no noticeable problems, especially when it is small. Many people only learn they have it during a routine eye exam.
Vision in one eye can become fuzzy or less sharp, which may make reading or recognizing faces harder on that side. Some may find that new glasses do not fully clear the blur.
Some people see brief flashes of light or new floaters drifting across their vision. These changes can happen if the tumor irritates the inside of the eye or causes fluid to build up.
A dark spot, curtain, or missing area can appear in part of the visual field. Day to day, it can feel like objects keep disappearing off to one side.
How people usually first notice Posterior uveal melanoma?
Posterior uveal melanoma often enters the story quietly: many people feel completely well at first, and the tumor is first spotted during a routine dilated eye exam when an eye doctor sees a dark or elevated area inside the back part of the eye. When symptoms do show up, the first warning signs are usually changes in vision, such as blurred vision, flashes of light, new floaters, a growing blind spot, or a shadow in part of the visual field, although some people with posterior uveal melanoma notice no symptoms at all. Because these changes can also happen with more common and less serious eye problems, the key takeaway is simple: any new or unexplained change in vision deserves prompt medical attention.
Types of Posterior uveal melanoma
Posterior uveal melanoma can show up in a few recognized patterns, and where the tumor starts often shapes what people notice day to day. In practice, the main types of posterior uveal melanoma are based on whether the cancer begins in the choroid or the ciliary body, and doctors also recognize a less common diffuse growth pattern. Symptoms don’t always look the same for everyone. Some people have early symptoms of posterior uveal melanoma such as blurred vision or flashes of light, while others have no obvious symptoms until an eye exam.
Choroidal melanoma
This is the most common type and starts in the choroid, the layer under the retina. Many people notice blurred vision, flashes, floaters, or a shadow in part of their sight, although small tumors may cause no symptoms at first. It is often found during a routine dilated eye exam.
Ciliary body melanoma
This type begins in the ciliary body, a structure near the front part of the posterior uvea. It can stay silent longer because it is harder to see and may not affect central vision early on. When symptoms do appear, they can include blurry vision, a change in the shape of the pupil, or eye discomfort from raised pressure.
Diffuse melanoma
This less common variant spreads more thinly across the inner eye wall instead of forming one rounded mass. Because of that flatter growth pattern, symptoms may be vague at first, such as slowly worsening vision or fluid under the retina. It can be harder to spot early and may look different from the more usual types of posterior uveal melanoma.
Can I slow down the onset of symptoms?
No, there is no good evidence that lifestyle changes or medicines can meaningfully delay the onset of posterior uveal melanoma, a rare cancer that starts in the back of the eye. Unlike some other conditions, no diet, exercise plan, supplement, or other daily habit has been proven to prevent it, although research is still looking at possible risk factors. There is no routine preventive medication, but regular dilated eye exams may help find changes earlier, especially if your eye doctor is already watching a spot in the eye or you have a strong family history, and while that cannot guarantee prevention, it is still a worthwhile step.
What genetics can tell you about symptoms
Genetics can sometimes give clues about how posterior uveal melanoma may behave, but it usually does not predict the exact day-to-day symptoms someone will notice. Certain gene changes in the tumor are linked more strongly to how aggressive the cancer is and how likely it is to spread, which can affect how quickly vision changes, flashes, floaters, or a dark spot in vision may develop, although many people have few or no symptoms at first. Inherited gene changes are less common, but in some families they can raise the risk of getting this cancer and may be linked with younger age at diagnosis.
Causes and risk factors
Doctors do not know the exact cause of posterior uveal melanoma, but it begins when pigment cells in the back of the eye pick up DNA changes and start growing abnormally. The main risk factors for posterior uveal melanoma include older age and having light-colored eyes, fair skin, or European ancestry. Inherited gene changes, including BAP1 in some families, can raise risk, and so can certain eye findings such as extra pigment in or around the eye or a freckle inside the eye. Researchers are still learning how these pieces fit together. Sun and ultraviolet light may play a part, but the link is less clear than it is for skin melanoma, and no single lifestyle habit is known to be a main cause.
What are the most common causes or risk factors?
Posterior uveal melanoma usually is not caused by anything a person did; most cases seem to happen when pigment cells in the back of the eye develop DNA changes over time. It is seen more often in older adults and in people with lighter-colored eyes, fair skin, and White or European ancestry. Risk is also higher in people born with certain inherited gene changes, especially in a gene called BAP1, and in those who have extra pigment in or around the eye or a mole inside the eye.
Environmental and biological risk factors
Posterior uveal melanoma is a rare eye cancer that starts in pigment-making cells in the back of the eye. Most known risk factors for posterior uveal melanoma are biological rather than environmental. Some risks are carried inside the body, others come from the world around us, but for this cancer the clearest links are mostly body-based.
Posterior uveal melanoma becomes more common with increasing age. It is uncommon in children and younger adults, and most cases are found later in life.
This cancer is seen more often in people with light-colored eyes and fair skin. It is also more common in people of Northern European ancestry than in those with darker natural pigmentation.
Extra pigment in the eye or the skin around it can raise the risk of posterior uveal melanoma. This is a strong known risk factor, even though the condition itself is uncommon.
A freckle inside the eye, called a choroidal nevus, is usually harmless. Still, a small number can change over time, so larger or unusual-looking nevi are watched more closely.
Genetic risk factors
Most cases of posterior uveal melanoma happen by chance and are not passed down through families. In many living with posterior uveal melanoma, the key DNA changes arise in the pigment cells inside the eye during life rather than being present from birth. Carrying a genetic change doesn’t guarantee the condition will appear. When doctors discuss the genetic risk factors for posterior uveal melanoma, they mainly mean rare inherited changes such as BAP1 and gene faults that develop inside the tumor, especially in GNAQ or GNA11.
GNAQ changes: Many posterior uveal melanomas begin with an acquired change in the GNAQ gene inside eye pigment cells. This change is usually found only in the tumor, not in the rest of the body.
GNA11 changes: GNA11 is another gene that commonly develops an acquired fault in posterior uveal melanoma. Like GNAQ changes, it usually helps explain how the tumor starts rather than pointing to a risk passed through a family.
Other driver genes: Less often, early tumor changes involve genes called CYSLTR2 or PLCB4. These are uncommon but well-recognized genetic causes in some cases of posterior uveal melanoma.
BAP1 changes: A rare inherited change in BAP1 can raise the chance of posterior uveal melanoma and some other cancers. Not everyone who carries this change will develop cancer, but a pattern of several related cancers in one family can be a clue. Genetic counseling may be worth discussing if that pattern is present.
Family history: Most people with posterior uveal melanoma do not have a close relative with the same disease. Still, when several family members have uveal melanoma or related cancers, doctors may look for an inherited cancer syndrome.
Lifestyle risk factors
For posterior uveal melanoma, lifestyle risk factors are much less clear than they are for many other cancers. Current research has not identified strong, proven habits that directly cause this eye melanoma, so discussions of lifestyle risk factors for posterior uveal melanoma need to be cautious. Still, some everyday habits may influence overall cancer health, inflammation, treatment tolerance, and the risk of complications.
Smoking is not a well-established direct cause of posterior uveal melanoma, but it can increase oxidative stress and damage blood vessels. That may be especially relevant for eye health and for recovery during or after cancer treatment.
Obesity has not been proven to specifically cause posterior uveal melanoma, but it can promote chronic inflammation and metabolic changes linked to worse cancer outcomes in general. It may also raise the risk of treatment-related complications and other illnesses that make care harder.
Physical inactivity is not a confirmed direct risk factor for posterior uveal melanoma, but regular movement supports cardiovascular health, energy, and physical resilience during treatment. Poor fitness may make fatigue, deconditioning, and recovery more difficult.
No specific diet has been shown to directly trigger posterior uveal melanoma, but a pattern high in ultra-processed foods and low in fruits, vegetables, and fiber may worsen metabolic health and inflammation. Good nutrition can matter for strength, healing, and tolerance of treatment even when it is not a proven cause of the tumor.
Risk prevention
Posterior uveal melanoma cannot always be prevented, because it often develops without a clear single cause. Still, some steps may help lower risk and support earlier detection, which matters because this cancer can grow quietly for a long time. Prevention is about lowering risk, not eliminating it completely.
Protecting your eyes from ultraviolet light may help reduce avoidable damage over time. Wearing sunglasses that block 99% to 100% of UVA and UVB rays and a wide-brimmed hat is a practical step outdoors.
Tanning beds expose the body to intense ultraviolet radiation, which may raise melanoma risk overall. Avoiding them is a sensible way to lower unnecessary exposure, even though the exact link to posterior uveal melanoma is still being studied.
Dilated eye exams can sometimes find posterior uveal melanoma before it causes symptoms or when early symptoms of posterior uveal melanoma are still easy to miss. This is especially important if you have light-colored eyes, fair skin, or a personal or family history of melanoma.
Some people have an inherited tendency to develop melanoma, including rare forms that affect the eye. If several relatives have had melanoma or unusual moles, genetic counseling may help clarify risk and guide screening.
Can you prevent Posterior uveal melanoma?
Posterior uveal melanoma, a rare cancer that starts in the back part of the eye, usually cannot be prevented, and there is no proven way to stop it from developing. Most of the main risk factors, such as older age, lighter eye color, fair skin, and some inherited traits, are not things you can change. Wearing UV-blocking sunglasses is sensible for overall eye health, but it has not been clearly proven to prevent this cancer; regular eye exams can help find it early, even though they do not prevent it.
Transmission
If you are living with posterior uveal melanoma, you do not need to worry about giving it to family members, friends, or coworkers through touch, kissing, sharing food, or being in the same room. Posterior uveal melanoma is not an infectious disease, so it cannot be caught like a cold or flu.
In most cases, posterior uveal melanoma is also not passed directly from parent to child. Rarely, some families have inherited gene changes that raise the risk of developing this cancer, so when people ask how posterior uveal melanoma is inherited, the answer is usually that the cancer itself is not inherited, but an increased tendency to develop it can be.
When to test your genes
For posterior uveal melanoma, gene testing is usually most useful after diagnosis: testing the tumor can estimate how likely it is to spread and help tailor eye, liver, and whole-body follow-up. Inherited gene testing may be worth discussing if you were diagnosed young or have a strong family history of uveal melanoma, mesothelioma, kidney cancer, or multiple unusual cancers.
Diagnosis
Posterior uveal melanoma is usually diagnosed after changes in vision or an eye exam raise concern, sometimes before it causes obvious symptoms. For many, the first step comes when everyday activities start feeling harder, such as reading, driving at night, or noticing new blurred spots. Doctors confirm the diagnosis of posterior uveal melanoma with a detailed eye exam and imaging tests rather than a routine blood test alone.
An eye specialist widens the pupil with drops and examines the back of the eye for a suspicious pigmented mass, fluid, or retinal changes. This is often the most important first step because the tumor can often be seen directly.
Ultrasound uses sound waves to measure the size, shape, and internal features of the tumor. These imaging findings can strongly support posterior uveal melanoma and help separate it from some benign growths.
Photos and scans such as optical coherence tomography and fluorescein angiography can show fluid, leakage, and changes in nearby retinal tissue. These tests help map the lesion and look for features linked with active melanoma.
Doctors usually begin by asking about vision changes, flashes, floaters, blind spots, and how quickly symptoms started. A detailed family and health history can help identify other eye conditions or cancer risks that may affect the workup.
How is Posterior uveal melanoma diagnosed?
Posterior uveal melanoma, a cancer that starts in the back part of the eye, is usually diagnosed by an eye cancer specialist during a dilated eye exam, where they look closely at the inside of the eye and measure the growth with imaging such as ultrasound and detailed eye scans or photographs. Doctors mainly base the diagnosis on how the spot looks, its size, shape, and whether it has features that suggest cancer rather than a harmless mole; only sometimes is a small tissue sample needed if the diagnosis is not clear. If tumor tissue is tested, genetic testing is mainly used to help estimate the chance of the cancer spreading, not usually to make the first diagnosis.
Stages of Posterior uveal melanoma
Posterior uveal melanoma is usually described in stages based on how large the tumor is and whether it has spread beyond the eye. In day-to-day terms, the stage helps doctors estimate how serious it is and what treatment may be most helpful. Doctors usually start with a conversation about symptoms, then use an eye exam and scans to work out the stages of posterior uveal melanoma. Sometimes answers come quickly, while other times it takes longer.
Stage 1
The melanoma is small and still limited to the eye. Some people have no symptoms, while others may notice blurred vision, flashes, or a shadow in part of their sight.
Stage 2
The tumor is larger but remains inside the eye. Vision changes often become more noticeable, and doctors may see fluid, retinal detachment, or pressure changes during the exam.
Stage 3
The cancer has grown further within the eye or into nearby structures around the eye. For many, this can mean more obvious vision loss, eye pain, or a visible change in the eye, though symptoms can still vary.
Stage 4
The melanoma has spread to other parts of the body, most often the liver. At this stage, symptoms may come from the eye, from the area where it has spread, or from both.
Outlook and prognosis
Outlook for posterior uveal melanoma depends mainly on tumor size, location, chromosome and gene-expression profile, and whether it has already spread outside the eye at diagnosis. Many patients can be treated successfully to preserve the eye or useful vision, but visual outcome is often limited if the tumor involves the macula or optic nerve or if radiation-related complications develop over time. The most important determinant of survival is metastasis, which occurs in roughly 30% to 50% of patients overall, often years after initial treatment, most commonly to the liver. For localized disease, 5-year melanoma-specific survival is generally around 70% to 85%, whereas metastatic posterior uveal melanoma carries a poor prognosis, with median survival often about 1 year despite newer systemic treatments modestly improving outcomes for some patients. Because metastatic risk can persist for decades, long-term surveillance is recommended even after apparently successful local therapy.
Long-term effects
Posterior uveal melanoma can affect life in two main ways over time: changes in vision from the tumor or its treatment, and the possibility that the cancer may spread elsewhere in the body. Some people do well for many years after treatment, while others need long-term follow-up because spread can happen later, even after the eye problem seems stable. Understanding the long-term effects of posterior uveal melanoma helps explain why doctors keep watching both the eye and the rest of the body over time.
Lasting blurred vision, missing areas in vision, or reduced sharpness can remain after posterior uveal melanoma or after treatment for it. For many, this can mean trouble reading fine print, driving, or noticing objects off to one side.
Some people develop ongoing eye problems such as flashes, floaters, distortion, or reduced depth perception. In some cases, the treated eye gradually loses useful sight over time.
A minority of people living with posterior uveal melanoma develop long-term discomfort if the eye becomes inflamed or pressure rises inside it. This can range from mild aching to a painful eye that no longer sees well.
When radiation is used, delayed damage to the retina, optic nerve, or blood vessels in the eye can appear months to years later. These changes may slowly worsen vision even when the tumor itself is controlled.
How is it to live with Posterior uveal melanoma?
Living with posterior uveal melanoma often means carrying two burdens at once: protecting your vision and coping with the uncertainty that comes with an eye cancer diagnosis. Many people living with it feel well at first, but daily life can shift around eye appointments, scans, treatment recovery, and possible changes in sight that can affect reading, driving, depth perception, and work, depending on the tumor and the treatment used. The impact also reaches the people around you, because family members may take on extra driving, childcare, or emotional support, and the need for long-term monitoring can keep everyone on edge, even when treatment goes well.
Treatment and drugs
Posterior uveal melanoma is usually treated with the goal of controlling the eye tumor while preserving as much vision and eye comfort as possible. Treatment plans often combine several approaches. Small to medium tumors are often treated with targeted radiation placed near the eye or aimed from outside the body, while some people may need laser treatment, surgery to remove the tumor, or removal of the eye if the cancer is large or causing severe pain. Drug treatment is less often used for the eye tumor itself, but if posterior uveal melanoma has spread, doctors may use cancer medicines such as immunotherapy or targeted therapy, and treatment may also include care aimed at the liver because that is a common place for spread. Not every treatment works the same way for every person, so regular follow-up scans and eye exams are an important part of care, and your doctor can explain which options best fit the stage of the cancer, your vision, and your overall health.
Can you cure Posterior uveal melanoma?
For many people with posterior uveal melanoma, treatment can get rid of the tumor in the back part of the eye, but there is no guaranteed cure because this cancer can sometimes come back or spread to other parts of the body, even years later. Treatment may include focused radiation, surgery, and sometimes laser treatment, and these can control the cancer, protect vision when possible, and lower the risk of spread. If the cancer has already spread, treatment usually aims to slow it down and manage symptoms rather than cure it.
Non-drug treatment
Treatment for posterior uveal melanoma usually centers on procedures that remove or destroy the tumor while trying to preserve as much vision and eye comfort as possible. Not every approach works the same way, and the best choice often depends on the tumor’s size, location, growth pattern, and whether useful vision can still be protected. For many, this can mean weighing a treatment that saves the eye against one that offers the safest control of the cancer. In day-to-day life, that may look like deciding between several clinic visits for radiation or a single operation if the tumor is large or causing pain.
This treatment places a small radioactive disc on the outside of the eye for a few days to target the tumor directly. It is one of the most common eye-sparing treatments for posterior uveal melanoma, especially for small to medium tumors.
This is a highly focused form of radiation that aims beams at the melanoma while limiting damage to nearby tissue. It may be used when the tumor sits close to important parts of the eye, such as the optic nerve or central retina.
Heat-based laser therapy may be used for selected small tumors or sometimes along with radiation. In some people, it can help control local growth, but it is not suitable for every tumor shape or location.
Surgery may remove just the tumor in selected cases, but more often it involves removing the eye if the melanoma is large or vision cannot be saved. Although making changes can feel daunting, this option can provide strong local control and may also relieve pain or pressure.
Your genes may have an impact on how drugs work for you
For most people with posterior uveal melanoma, inherited gene differences are not yet a routine way to choose the main treatment, since care is usually based more on the size and spread of the tumor and on changes found in the tumor itself. Still, many living with this cancer may respond a little differently to medicines used along the way, such as drugs for pain, nausea, or some cancer treatments, because the body can break down medicines faster or slower from one person to another. In day-to-day terms, that can mean one person gets good relief with few problems while another has stronger side effects or needs a different dose, so doctors may adjust treatment based on how the medicine is working for them.
Pharmacological treatments
Drug treatment for posterior uveal melanoma is used most often when the cancer has spread or cannot be fully controlled with local treatment alone. Medication can feel like a big step, but for many living with posterior uveal melanoma, medicines are only part of the treatment plan, alongside radiation, surgery, or liver-directed care. The drug choice depends on where the melanoma has spread, overall health, and, in some cases, a blood test called HLA-A*02:01. There is no single medicine that works for everyone, and drugs tend to help metastatic disease more than the original eye tumor.
Tebentafusp is the main drug specifically approved for some adults with metastatic posterior uveal melanoma who test positive for HLA-A*02:01. It helps the immune system find and attack melanoma cells, and it is often the first systemic treatment considered in that setting. Early symptoms of posterior uveal melanoma usually come from the eye itself, but tebentafusp is used after the disease has spread, not for those first eye symptoms.
Ipilimumab and nivolumab are immunotherapy drugs that can be used together when posterior uveal melanoma has spread. This combination may help some people more than a single drug, but side effects can be more intense because it revs up the immune system more strongly.
Nivolumab or pembrolizumab may be used alone, especially if combination treatment is not a good fit. These medicines are generally easier to tolerate than two-drug immunotherapy, although they often have more limited benefit in uveal melanoma than in skin melanoma.
Drugs such as dacarbazine or temozolomide have been used for metastatic posterior uveal melanoma, but they usually have modest effects. They may still be considered when newer options are not available or have stopped working.
Genetic influences
Hearing that a tumor has genetic changes can make it seem as if it must run in the family, but with posterior uveal melanoma that is usually not the case. Most people with posterior uveal melanoma develop it because DNA changes arise in the eye’s pigment cells during life, not because they inherited the condition from a parent. Certain gene changes help start the cancer, and others help doctors judge how likely it is to grow, return, or spread, especially to the liver. Having a genetic risk is not the same as having the disease itself. A small number of people do have an inherited risk, most often linked to a gene called BAP1, so doctors may suggest genetic counseling or genetic testing for posterior uveal melanoma when there is a strong family history, diagnosis at a younger age, or a pattern of related cancers in the family. Testing the tumor itself can also help guide follow-up care, but those results do not always mean a gene change was inherited.
Is Posterior uveal melanoma genetic?
Genetics matter a lot in posterior uveal melanoma. Most cases are not inherited, but gene changes in the tumor help guide prognosis, and rarely an inherited change can raise risk for posterior uveal melanoma in families.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are widely present in the general population. Most of these variants do not have a direct impact on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. In some situations, however, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with posterior uveal melanoma, treatment decisions often depend less on inherited genes and more on the genetic changes found in the tumor itself. Testing the melanoma can reveal changes in genes such as GNAQ, GNA11, BAP1, or SF3B1, which helps doctors estimate how the cancer may behave and how closely to monitor for spread, especially to the liver. In earlier disease, those results usually do not change the main local treatments, such as radiation or surgery, but they can affect follow-up plans and whether genetic testing for posterior uveal melanoma may support enrollment in a clinical trial. In more advanced disease, genetics can matter more directly because the drug tebentafusp is only used for people with a specific inherited immune-system marker called HLA-A*02:01. Not every difference in response is genetic, but tumor testing and HLA testing can help match some people to newer treatments or studies when standard options are limited. Because this area is still evolving, it is reasonable to ask your cancer team whether tumor gene testing or HLA testing could affect your treatment plan.
Interactions with other conditions
Posterior uveal melanoma can be harder to spot because its symptoms may overlap with more common eye problems, such as blurry vision, flashes, floaters, or a shadow in part of the visual field. In some people, cataracts, age-related macular degeneration, diabetic eye disease, or glaucoma may already be affecting sight, so early symptoms of posterior uveal melanoma can be mistaken for another condition or simply added to existing vision changes. Doctors call it a comorbidity when two conditions occur together. This matters because other eye diseases can delay diagnosis, and some treatments for posterior uveal melanoma may also affect vision that is already limited by another eye problem. The most important medical interaction is with cancer spread, especially to the liver, so people living with posterior uveal melanoma often need follow-up that looks beyond the eye as well as at it. If someone also has serious liver disease or other major health conditions, the care plan may need to be adjusted to balance cancer treatment, monitoring, and overall health.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Posterior uveal melanoma?
Other problems in the back of the eye can look or feel similar to posterior uveal melanoma, especially a harmless eye freckle or mole, a retinal detachment, bleeding under the retina, and age-related macular degeneration. In some cases, doctors also need to tell it apart from cancer that has spread to the eye from another part of the body, because these conditions can all cause blurred vision, flashes, floaters, or a shadow in part of the vision.
History
People living with posterior uveal melanoma are often diagnosed after a routine eye exam, which can make the condition feel especially unsettling. Unlike cancers that cause obvious early changes, this one may stay quiet for some time, so its history is closely tied to the history of eye examinations themselves.
Since the earliest medical writings, doctors have described dark growths inside the eye, although they could not clearly tell one kind from another. For many years, these tumors were only recognized after they had grown large enough to affect vision or cause pain. As tools for looking into the eye improved in the 1800s, especially the ophthalmoscope, doctors became much better at seeing tumors in the back of the eye while a person was still alive rather than only after surgery or death.
In the late 19th and early 20th centuries, posterior uveal melanoma became more clearly separated from other eye diseases that can look similar, such as retinal problems or harmless pigmented spots. Doctors also began to notice that not every case behaved the same way. Some tumors stayed small for a time, while others grew and spread, which helped shape the modern understanding that careful monitoring and early treatment matter.
Treatment changed a great deal over the past century. In earlier decades, removal of the eye was often the main option, mainly because there were few reliable ways to control the tumor and protect sight at the same time. Later, radiation treatments and more precise imaging gave many people with posterior uveal melanoma a chance to treat the cancer without always removing the eye. This shift was important in everyday life: for some, it meant keeping useful vision long enough to keep driving, reading, or working more normally during treatment.
Research has continued to refine care. Doctors now better understand which tumors are more likely to grow or spread, and genetic research later showed that posterior uveal melanoma has a biological basis that can help guide prognosis, even though this does not change the need for regular follow-up. Looking back helps explain why modern care places so much emphasis on early detection, eye imaging, and long-term monitoring after treatment.